Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel Plus Gemcitabine in Advanced Urothelial Carcinoma
NCT02887248Phase 2Terminated
- Sponsor
- SCRI Development Innovations
- Start
- Jan 2017
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of paclitaxel in urothelial carcinoma (UC), sponsored by SCRI Development Innovations. Started Jan 2017; status: terminated.
02
Drugs
paclitaxel
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT02887248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02887248.